This phase I trial will evaluate whether stereotactic ablative radiotherapy (SABR) is a safe and effective treatment option for patients with non-small cell lung cancer (NSCLC) whose cancer is large and/or has spread to the nearby lymph nodes.
This trial is treating patients with non-small cell lung cancer.
This is a radiotherapy trial.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Scientific Title
Treatment of Locally Advanced non-small cell lung carcinoma with Stereotactic ablativE Radiotherapy
Other Non-Commercial Sponsor
Alfred Health
Summary
Stereotactic ablative radiotherapy (SABR) is a specialised form of radiotherapy whereby large doses of radiation are given in fewer treatments. Patients participating in this trial will attend between 6-12 SABR sessions across 2-3 weeks, and will then be followed up regularly post radiotherapy, in order to evaluate treatment safety, quality of life, tumour response and survival.
Recruiting Hospitals Read More